stella
beta
Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer — Stella
Recruiting
Back to High Risk Cancer trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(1 site)
United States
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
View full record on ClinicalTrials.gov